1. Home
  2. RXRX vs NVCR Comparison

RXRX vs NVCR Comparison

Compare RXRX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RXRX
  • NVCR
  • Stock Information
  • Founded
  • RXRX 2013
  • NVCR 2000
  • Country
  • RXRX United States
  • NVCR Jersey
  • Employees
  • RXRX N/A
  • NVCR N/A
  • Industry
  • RXRX Biotechnology: Pharmaceutical Preparations
  • NVCR Medical/Dental Instruments
  • Sector
  • RXRX Health Care
  • NVCR Health Care
  • Exchange
  • RXRX Nasdaq
  • NVCR Nasdaq
  • Market Cap
  • RXRX 2.0B
  • NVCR 1.8B
  • IPO Year
  • RXRX 2021
  • NVCR 2015
  • Fundamental
  • Price
  • RXRX $6.97
  • NVCR $18.10
  • Analyst Decision
  • RXRX Buy
  • NVCR Buy
  • Analyst Count
  • RXRX 6
  • NVCR 5
  • Target Price
  • RXRX $9.40
  • NVCR $26.60
  • AVG Volume (30 Days)
  • RXRX 4.1M
  • NVCR 1.3M
  • Earning Date
  • RXRX 11-06-2024
  • NVCR 10-30-2024
  • Dividend Yield
  • RXRX N/A
  • NVCR N/A
  • EPS Growth
  • RXRX N/A
  • NVCR N/A
  • EPS
  • RXRX N/A
  • NVCR N/A
  • Revenue
  • RXRX $49,635,000.00
  • NVCR $577,738,000.00
  • Revenue This Year
  • RXRX $57.90
  • NVCR $16.26
  • Revenue Next Year
  • RXRX $35.23
  • NVCR $6.29
  • P/E Ratio
  • RXRX N/A
  • NVCR N/A
  • Revenue Growth
  • RXRX N/A
  • NVCR 14.63
  • 52 Week Low
  • RXRX $5.04
  • NVCR $10.87
  • 52 Week High
  • RXRX $15.74
  • NVCR $24.74
  • Technical
  • Relative Strength Index (RSI)
  • RXRX 56.62
  • NVCR 60.81
  • Support Level
  • RXRX $6.22
  • NVCR $15.89
  • Resistance Level
  • RXRX $6.90
  • NVCR $17.69
  • Average True Range (ATR)
  • RXRX 0.32
  • NVCR 1.01
  • MACD
  • RXRX 0.04
  • NVCR 0.14
  • Stochastic Oscillator
  • RXRX 90.64
  • NVCR 89.55

About RXRX Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

About NVCR NovoCure Limited

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Share on Social Networks: